image credit: Freepik

Addressing manufacturing challenges in gene therapy development

March 20, 2023

Gene therapy is on the rise. As clinical success, innovation and investment in this area strengthens, Precedence Research predicts that the cell and gene therapy market will grow at a CAGR of 22 percent by 2030. Additionally, the FDA expects it will approve 10 to 20 cell and gene therapy products a year starting in 2025, based on the current clinical pipeline. Minh Hong, Ph.D., head of commercial, viral vector CDMO services with MilliporeSigma, says that this growth is a reflection of the vast potential that gene therapy offers patients.

Read More on Biopharma Dive